
Enable job alerts via email!
Generate a tailored resume in minutes
Land an interview and earn more. Learn more
A leading biopharmaceutical company is seeking a Cell Therapy Account Manager in Saudi Arabia. This role is pivotal in building relationships with treatment centers to drive the use of innovative CAR T therapies. Key responsibilities include account management, operational coordination, and supporting strategic initiatives. Ideal candidates should possess a licensed pharmacist degree and significant experience in oncology account management, alongside a strong clinical background in hematology and cell therapy logistics. Travel of 30-40% is expected.
The Cell Therapy Account Manager (CTAM) has primary responsibility for developing the relationship with Kite’s Authorized Treatment Centers (ATCs) in Saudi Arabia and serves as the ATC’s primary point of contact with Kite. In this role, the CTAM is responsible for driving appropriate utilization of Kite’s CAR T therapies within the account and ensuring the delivery of a seamless customer experience. To accomplish these goals, the CTAM will cultivate strong relationships with account stakeholders, coordinate all of Kite’s activities within the ATC, develop strategic account plans and communicate the value of CAR T therapy to key account stakeholders. This position is field based.
Everyone at Kite is grounded by one common goal – curing cancer. We are at the forefront of immunotherapy and engineered T cell therapy. Our personalized approach is what sets us apart. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. With CAR T-cell therapy, we are reengineering a patient’s own immune cells to fight cancer — one patient at a time. We also are entering a pivotal time in our history with multiple planned launches and evolving competitive dynamics on a global scale. That means a fast moving, constantly changing environment and innovative culture, where we make discoveries every day – discoveries that include our own capabilities and our individual potential.
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long‑term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system’s ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com.